|
Jul 21
|
S&P 500, Nasdaq Scale New Highs in Broad-Based Rally
|
|
Jul 21
|
Target downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
|
|
Jul 21
|
Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm
|
|
Jul 21
|
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
|
|
Jul 18
|
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
|
|
Jul 18
|
Here's What to Expect From Biogen's Next Earnings Report
|
|
Jul 17
|
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
|
|
Jul 17
|
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
|
|
Jul 10
|
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT
|
|
Jul 10
|
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
|
|
Jul 10
|
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
|
|
Jul 10
|
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT
|
|
Jul 8
|
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
|
|
Jul 1
|
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
|
|
Jul 1
|
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
|
|
Jun 30
|
AbbVie to buy Capstan for up to $2.1 billion in immunology push
|
|
Jun 30
|
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
|
|
Jun 30
|
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
|
|
Jun 28
|
Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials
|
|
Jun 28
|
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
|